Search Results
You are looking at 21 - 30 of 65 items for
- Author or Editor: Noah Cohen x
- Refine by Access: All Content x
Abstract
Objective—To determine the effects of treatment with platelet- and leukocyte-rich plasma (PRP) on future 2-, 3-, and 4-year-old racing performance of yearling Thoroughbreds with proximal sesamoid bone inflammation and associated suspensory ligament branch (SLB) desmitis.
Design—Randomized clinical trial.
Animals—39 yearling Thoroughbreds.
Procedures—Yearling Thoroughbreds with radiographic evidence of performance-limiting proximal sesamoid bone inflammation and ultrasonographic evidence of associated SLB desmitis were identified and randomly assigned to undergo PRP (treatment group) or saline (0.9% NaCl) solution (control group) injection at the affected SLB-proximal sesamoid bone junction. Race records of horses for the 2-, 3-, and 4-year-old racing years were obtained. Data regarding amount of money earned and number of races started were used as outcome measures, and results for groups were compared.
Results—Horses treated with PRP were significantly more likely to start at least 1 race during the 2-year-old racing year than were horses treated with saline solution; no significant differences were detected between groups regarding that variable for the 3- and 4-year-old racing years. No significant differences between groups were detected regarding earnings for any racing year.
Conclusions and Clinical Relevance—Although PRP-treated horses were more likely to start a race during the 2-year-old racing year versus control group horses, results for horses in each group were not significantly different for the 3- and 4-year-old racing years. Therefore, the PRP treatment protocol evaluated in this study did not seem to improve future racing performance of yearling Thoroughbreds with proximal sesamoid bone inflammation and associated SLB desmitis, compared with injection of saline solution.
Abstract
Objective—To quantify the number of horses with Corynebacterium pseudotuberculosis infection identified in the United States from January 2003 through December 2012.
Design—Cross-sectional study.
Sample—State veterinary diagnostic laboratory records of 2,237 C pseudotuberculosis culture-positive samples from horses.
Procedures—44 state veterinary diagnostic laboratories throughout the United States were invited by mail to participate in the study. Data requested included the number of C pseudotuberculosis culture-positive samples from horses identified per year, geographic location from which the C pseudotuberculosis culture-positive sample was submitted, month and year of sample submission, breed and age of horses, and category of clinical manifestation (ie, internal infection, external infection, or ulcerative lymphangitis).
Results—Of the 44 invited laboratories, 15 agreed to participate and provided data on affected horses from 23 states. The proportion of C pseudotuberculosis culture-positive samples submitted during 2011 through 2012 (1,213/2,237 [54%]) was significantly greater than that for the period from 2003 through 2010 (1,024/2,237 [46%]). Corynebacterium pseudotuberculosis was recovered from horses in states where the disease has not been previously recognized as endemic. Affected horses were identified year-round. The greatest proportion of C pseudotuberculosis culture-positive samples was identified during November, December, and January (789/2,237 [35%]). No significant association between the clinical form of disease and age or breed of horse was observed.
Conclusions and Clinical Relevance—The occurrence of C pseudotuberculosis infection in horses increased during the 10-year period, and affected horses were identified throughout the United States. Further studies to determine changes in annual incidence and to identify potential changing climatic conditions or vector populations associated with disease transmission are warranted to help control the occurrence and spread of C pseudotuberculosis infection in horses.
Abstract
Objective—To determine the pharmacokinetics of gallium maltolate (GaM) after intragastric administration in healthy foals.
Animals—6 healthy neonatal foals.
Procedures—Each foal received GaM (20 mg/kg) by intragastric administration. Blood samples were obtained before (time 0) and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, and 48 hours after GaM administration for determination of serum gallium concentrations by use of inductively coupled plasma mass spectroscopy.
Results—Mean ± SD pharmacokinetic variables were as follows: peak serum gallium concentration, 1,079 ± 311 ng/mL; time to peak serum concentration, 4.3 ± 2.0 hours; area under the serum concentration versus time curve, 40,215 ± 8,420 ng/mL/h; mean residence time, 39.5 ± 17.2 hours; area under the moment curve, 1,636,554 ± 931,458 ng([h]2/mL); and terminal half-life, 26.6 ± 11.6 hours. The mean serum concentration of gallium at 12 hours was 756 ± 195 ng/mL.
Conclusions and Clinical Relevance—Gallium maltolate administered via nasogastric tube at a dose of 20 mg/kg to neonatal foals resulted in gallium serum concentrations considered sufficient to suppress growth or kill Rhodococcus equi in macrophages and other infected tissues.
Abstract
Objective—To determine concentrations of 2 acute-phase proteins (serum amyloid A [SAA] and lipopolysaccharide-binding protein [LBP]) in serum samples obtained from horses with colic and identify relationships among these acute-phase proteins and clinical data.
Animals—765 horses with naturally developing gastrointestinal tract diseases characterized by colic (ie, clinical signs indicative of abdominal pain) and 79 healthy control horses; all horses were examined at 2 university teaching hospitals.
Procedure—Serum concentrations of SAA and LBP were determined by immunoturbidometric and dotblot assays, respectively.
Results—SAA and LBP concentrations were determined for 718 and 765 horses with colic, respectively. Concentrations of SAA were significantly higher in nonsurvivors than in survivors, and horses with enteritis or colitis and conditions characterized by chronic inflammation (eg, abdominal abscesses, peritonitis, or rectal tears) had SAA concentrations significantly greater than those for horses with other conditions. Serum concentrations of LBP did not correlate with outcome, disease process, or portion of the gastrointestinal tract affected.
Conclusions and Clinical Relevance—Circulating concentrations of SAA were significantly higher at admission in horses with colic attributable to conditions having a primary inflammatory cause (eg, enteritis, colitis, peritonitis, or abdominal abscesses) and were higher in horses that failed to survive the episode of colic, compared with concentrations in horses that survived. Serum concentrations of LBP did not correlate with survival. Analysis of these findings suggests that evaluation of SAA concentrations may be of use in identifying horses with colic attributable to diseases that have inflammation as a primary component of pathogenesis. (Am J Vet Res 2005;66:1509–1516)
Abstract
Objective—To determine the pharmacokinetics of gallium maltolate (GaM) after intragastric administration in adult horses.
Animals—6 adult horses.
Procedures—Feed was withheld for 12 hours prior to intragastric administration of GaM (20 mg/kg). A single dose of GaM was administered to each horse via a nasogastric tube (time 0). Blood samples were collected at various time points from 0 to 120 hours. Serum was used to determine gallium concentrations by use of inductively coupled plasma-mass spectroscopy. Noncompartmental and compartmental analyses of serum gallium concentrations were performed. Pharmacokinetic models were selected on the basis of the Akaike information criterion and visual analysis of plots of residuals.
Results—Serum concentration data for 1 horse were such that this horse was considered an outlier and excluded from noncompartmental and compartmental analyses. Noncompartmental analysis was used to determine individual pharmacokinetic parameters. A 1-compartment model with first-order input and output and lag time was selected as the best-fit model for the data and used to determine mean — SD values for maximum observed serum concentration (0.28 — 0.09 μg/mL), time of maximum concentration (3.09 — 0.43 hours), time to the first measurable concentration (0.26 — 0.11 hours), apparent elimination half-life (48.82 — 5.63 hours), area under the time-concentration curve (20.68 — 757 h—μg/mL), and apparent volume of distribution (73,493 — 18,899 mL/kg).
Conclusion and Clinical Relevance—Further studies are necessary to determine the bioavailability of GaM after intragastric administration in adult horses.
Abstract
Objective—To determine the chemoprophylactic effect of gallium maltolate on the cumulative incidence of pneumonia caused by Rhodococcus equi infection in foals.
Animals—483 foals born and raised on 12 equine breeding farms with a history of endemic R equi infections.
Procedures—Group 1 foals were treated with a placebo and group 2 foals were treated with gallium maltolate (approx 30 mg/kg, PO, q 24 h) during the first 2 weeks after birth. Foals were monitored for development of pneumonia attributable to R equi infection and for adverse effects of gallium maltolate.
Results—There were no significant differences in the cumulative incidence of R equi pneumonia among the 2 groups.
Conclusions and Clinical Relevance—Chemoprophylaxis via gallium maltolate administered orally at approximately 30 mg/kg daily for the first 2 weeks after birth failed to reduce the cumulative incidence of pneumonia attributable to R equi infection among foals on breeding farms with endemic R equi infections. Further investigation is needed to identify strategies for control of R equi infections.
Abstract
Objective—To estimate spatial risks associated with mare reproductive loss syndrome (MRLS) during 2001 among horses in a specific study population and partition the herd effects into those attributable to herd location and those that were spatially random and likely attributable to herd management.
Animals—Pregnant broodmares from 62 farms in 7 counties in central Kentucky.
Procedure—Veterinarians provided the 2001 abortion incidence proportions for each farm included in the study. Farms were georeferenced and data were analyzed by use of a fully Bayesian risk-mapping technique.
Results—Large farm-to-farm variation in MRLS incidence proportions was identified. The farm-to-farm variation was largely attributed to spatial location rather than to spatially random herd effects
Conclusions and Clinical Relevance—Results indicate that there are considerable data to support an ecologic cause and potential ecologic risk factors for MRLS. Veterinary practitioners with more detailed knowledge of the ecology in the 7 counties in Kentucky that were investigated may provide additional data that would assist in the deduction of the causal factor of MRLS via informal geographic information systems analyses and suggest factors for inclusion in further investigations. (Am J Vet Res 2005;66:17–20)
Abstract
Objective—To characterize the temporality of dates of breeding and abortion classified as mare reproductive loss syndrome (MRLS) among mares with abortions during early gestation.
Animals—2,314 mares confirmed pregnant at approximately 28 days after breeding from 36 farms in central Kentucky, including 515 mares that had earlyterm abortions.
Procedure—Farm veterinarians and managers were interviewed to obtain data for each mare that was known to be pregnant to determine pregnancy status, breeding date, last date known to be pregnant, and date of abortion.
Results—Mares bred prior to April 1, 2001, appeared to be at greatest risk of early-term abortion, both among and within individual farms. Mares bred in mid-February appeared to be at greatest risk of abortion, with an estimated weekly incidence rate of abortion of 66% (95% CI, 52% to 80%).
Conclusions and Clinical Relevance—Mares in central Kentucky bred between mid-February and early March were observed to be at greatest risk of early-term abortion, and risk gradually decreased to a background incidence of abortion of approximately 11%. Mares bred after April 1, 2001, appeared to be at markedly less risk, indicating that exposure to the cause of MRLS likely occurred prior to this date. (Am J Vet Res 2005;66:1792–1797)
Abstract
Objective—To evaluate a real-time quantitative polymerase chain reaction (QPCR) assay in the detection and quantitation of virulent Rhodococcus equi.
Sample Population—1 virulent, 2 intermediately virulent, and 2 avirulent strains of R equi and 16 isolates of bacteria genetically related to R equi.
Procedure—The QPCR assay was evaluated for detection and quantitation of the virulence-associated gene (vapA) of R equi in pure culture and in samples of tracheobronchial fluid, which were inoculated with known numbers of virulent R equi. Results were compared with those derived via quantitative microbial culture and standard polymerase chain reaction methods.
Results—The QPCR assay detected the vapAgene in pure culture of R equi and in tracheobronchial fluid samples that contained as few as 20 CFUs of virulent R equi/mL and accurately quantitated virulent R equi to 103 CFUs/mL of fluid. The assay was highly specific for detection of the vapA gene of virulent R equi and was more sensitive than standard polymerase chain reaction for detection of R equi in tracheobronchial fluid.
Conclusions and Clinical Relevance—The QPCR assay appears to be a rapid and reliable method for detecting and quantitating virulent R equi. The accuracy of the QPCR assay is comparable to that of quantitative microbial culture. The increased sensitivity of the QPCR method in detection of virulent R equi should facilitate rapid and accurate diagnosis of R equi pneumonia in foals. (Am J Vet Res 2005;66:755–761)
Abstract
Objective—To determine whether administration of killed West Nile virus vaccine was associated with pregnancy loss among broodmares.
Design—Retrospective cohort study.
Animals—595 mares.
Procedure—Records of pregnant mares with known vaccination history from 4 farms were reviewed. Information obtained from 595 mares included mare's identification; farm; age; breed; reproductive status; last breeding date; date last known pregnant; vaccination date; age of conceptus at vaccination; vaccination during the early embryonic, early fetal, and late fetal periods; and whether an early embryonic death (EED), early fetal loss (EFL), or late fetal loss (LFL) occurred. The relationships between the dichotomous outcomes of loss (eg, EED, EFL, LFL) and independent categoric variables (eg, vaccination during the early embryonic, early fetal, or late fetal periods) were examined.
Results—Vaccination of pregnant mares during any period of gestation was not associated with increased incidence of pregnancy loss.
Conclusions and Clinical Relevance—Many mares are already pregnant at the onset of mosquito season, when mares are more likely to be vaccinated than at other times. Our findings provide evidence that vaccine administration will not compromise pregnancy in horses. (J Am Vet Med Assoc 2004;225:1894–1897)